Shimla Online

Diabetic Macular Edema Pipeline Analysis: 60+ Key Players | DelveInsight

 Breaking News
  • No posts were found

Diabetic Macular Edema Pipeline Analysis: 60+ Key Players | DelveInsight

November 15
01:12 2022
Diabetic Macular Edema Pipeline Analysis: 60+ Key Players | DelveInsight

DelveInsight’s, Diabetic Macular Edema Pipeline Insight, 2022,” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Key takeaways from the Diabetic Macular Edema Pipeline Insight Report

  • Diabetic Macular Edema Pipeline report offers a comprehensive analysis of 60+key players and 65+key therapies.
  • The leading Diabetic Macular Edema Companies such as Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
  • Promising Diabetic Macular Edema Pipeline therapies such as MYL-1701P, KSI-301, CT-P42, and others
  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic macular edema R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic macular edema.

 

Recent Breakthroughs of Diabetic Macular Edema Treatment Landscape

  • Recent randomized clinical trials have shown anti-vascular endothelial growth factor (VEGF) therapy improved visual acuity and macular swelling, and currently, it has become the first line of the treatment of DME. Anti-VEGF drugs have become the gold standard for the treatment of DME.
  • Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, implants, or injections of sustained-release corticosteroids into or around the eye.
  • OPT-302 (Opthea Limited) binds to VEGF receptor 2 and 3, neutralizing the activity of VEGF-C and –D and is being developed by the company for the treatment of patients with Diabetic Macular Edema.
  • ALG-1001 (Allegro Ophthalmics) is a first-in-class integrin peptide therapy. The molecule is able to bind specific integrin receptor sites and works by affecting multiple angiogenic pathways and inflammation. ALG-1001 showed promising results in the phase IIb clinical trial that evaluated it as a sequential therapy or in combination with bevacizumab in patients with DME.

 

Request a sample and discover the recent advances in Diabetic Macular Edema Medication @ Diabetic Macular Edema Treatment Landscape

 

Diabetic Macular Edema Overview

Diabetic Macular Edema (DME) is an eye condition which can occur in people living with diabetes – both type 1 and type 2. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, fluid can leak into the center of the macula, called the fovea, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called DME. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. Vision changes due to DME are: Blurred vision, Double vision, and Sudden increase in eye floaters. A detailed history including the approximate date of onset of diabetes, the use of insulin vs. oral antihyperglycemic agents, and the quality of metabolic control (e.g., HbA1c level) should be elicited. Maintaining good blood sugar, blood pressure, and cholesterol control helps prevent DME. Receiving a comprehensive dilated eye exam at least once a year, or more often as directed by the eye doctor. Laser light is used to close and destroy leaking blood vessels. This form of laser therapy does not typically cause pain. The treatment may leave permanent blind spots in a person’s vision. Anti-vascular endothelial growth factor (anti-VEGF) drugs block the development of new blood vessels and limit the leakage from the abnormal blood vessels in the eye.

 

Diabetic Macular Edema Emerging Drugs

MYL-1701P: Mylan Pharmaceuticals

MYL-1701P (also referred to as M710, as part of a partnership with Momenta Pharmaceuticals) is perhaps the aflibercept biosimilar that is furthest along in the development process. It is currently the subject of a 324-patient phase III trial. Mylan is to handle development and commercialization.  

KSI-301: Kodiak sciences

KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform KSI-301 is designed to have extended ocular half-life, higher potency, and improved ocular tissue bioavailability. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their DME with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. In addition, KSI-301 is designed to halt and reverse DR progression with long-term efficacy that can reduce the risk of vision-threatening complications from DR. The Phase III GLEAM and GLIMMER studies are global, multi-center, randomized studies designed to evaluate the efficacy, durability and safety of KSI-301 in patients with treatment-naïve diabetic macular edema (DME). 

CT-P42: Celltrion

CT-P42, an aflibercept biosimilar referencing Regeneron’s Eylea. The trial will enroll 300 patients with diabetic macular edema, and aims to compare CT-P42’s efficacy, safety, pharmacokinetics, and immunogenicity against Eylea.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of diabetic macular edema (DME)

 

Diabetic Macular Edema Pipeline Therapeutic Assessment

There are approx. 60+ key companies which are developing the therapies for Diabetic macular edema. The companies which have their Diabetic macular edema drug candidates in the most advanced stage, i.e. Phase III include, Mylan Pharmaceuticals.

 

DelveInsight’s Diabetic Macular Edema Pipeline report covers around 65+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Diabetic Macular Edema pipeline therapies @ Diabetic Macular Edema Clinical Trials

 

Scope of the Diabetic Macular Edema Pipeline Insight Report

  • Coverage- Global
  • Diabetic Macular Edema Pipeline Assessment by Product Type
  • Diabetic Macular Edema Pipeline Assessment by Stage and Product Type
  • Diabetic Macular Edema Pipeline Assessment by Route of Administration
  • Diabetic Macular Edema Pipeline Assessment by Stage and Route of Administration
  • Diabetic Macular Edema Pipeline Assessment by Molecule Type
  • Diabetic Macular Edema Pipeline Assessment by Stage and Molecule Type
  • Diabetic Macular Edema Companies- Mylan Pharmaceuticals, Kodiak sciences, Celltrion, Exonate, Opthea, AsclepiX Therapeutics, Allgenesis Biotherapeutics, Ascentage Pharma, Rezolute, Ocuphire Pharma, Oxurion, MingSight Pharmaceuticals, Adverum Biotechnologies, and others.
  • Diabetic Macular Edema Pipeline Therapies- MYL-1701P, KSI-301, CT-P42, and others

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Diabetic macular edema: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. MYL-1701P: Mylan Pharmaceuticals
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I)
  13. Drug Name: Company Name
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Diabetic macular edema Key Companies
  17. Diabetic macular edema Key Products
  18. Diabetic macular edema- Unmet Needs
  19. Diabetic macular edema- Market Drivers and Barriers
  20. Diabetic macular edema- Future Perspectives and Conclusion
  21. Diabetic macular edema Analyst Views
  22. Diabetic macular edema Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetic Macular Edema drugs?
  • How many Diabetic Macular Edema drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Macular Edema?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Macular Edema therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Macular Edema and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Diabetic macular edema Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles